Asieris Pharmaceuticals, founded in March 2010 in what’s known as China’s Medical City of Taizhou, Jiangsu Province, is the only China-based, globally oriented company specializing in the research and development of new drugs for the treatment of genitourinary tumors and related diseases.
Our professional teams are located in Shanghai, Beijing, and Taizhou, as well as in the United States, with departments responsible for domestic and international clinical development, regulatory affairs, pharmaceutical sciences, new drug discovery, and business development.
With our focus on genitourinary tumors and related diseases, our primary goal is to establish a leading position in this field with our own unique strategies. Through the “twin engines” of proprietary R&D and in-licensing, we explore the global values of proprietary first-in-class new drugs of breakthrough potential. Meanwhile, we license late-stage or newly marketed drugs from overseas for the Chinese market to enhance our product pipeline and allow us to quickly establish our leadership position in the domestic market.